Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14997157 | 1.00 | CA2 (0.31) | CA2 | |
| SCHEMBL2259710 | 0.77 | UGT2B7 (0.31) | — | |
| SCHEMBL8176947 | 0.77 | UGT2B7 (0.31) | — | |
| SCHEMBL2259704 | 0.77 | UGT2B7 (0.31) | — | |
| SCHEMBL3174753 | 0.75 | CA2 (0.34) | CA2 | |
| SCHEMBL1296437 | 0.75 | CA2 (0.34) | CA2 | |
| SCHEMBL15209865 | 0.75 | CA2 (0.34) | CA2 | |
| SCHEMBL3182979 | 0.75 | CA2 (0.34) | CA2 | |
| SCHEMBL1296434 | 0.75 | CA2 (0.34) | CA2 | |
| SCHEMBL11713937 | 0.75 | CA2 (0.34) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688707-B2 | Bicyclic morpholino compounds and oligomeric compounds prepared therefrom | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688707-B2 | Bicyclic morpholino compounds and oligomeric compounds prepared therefrom | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160186175-A1 | BICYCLIC MORPHOLINO COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | IONIS PHARMACEUTICALS, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160186175-A1 | BICYCLIC MORPHOLINO COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | IONIS PHARMACEUTICALS, INC. (US) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160186175-A1 | BICYCLIC MORPHOLINO COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | HNRNPM, UPF1, METTL16 | CA2 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.